In the BioHarmony Drug Report Database

"Preview" Icon

Avelumab

Bavencio (avelumab) is an antibody pharmaceutical. Avelumab was first approved as Bavencio on 2017-03-23. It is used to treat merkel cell carcinoma and transitional cell carcinoma in the USA. It has been approved in Europe to treat neuroendocrine tumors. The pharmaceutical is active against programmed cell death 1 ligand 1.

 

Trade Name

 

Bavencio
 

Common Name

 

avelumab
 

ChEMBL ID

 

CHEMBL3833373
 

Indication

 

merkel cell carcinoma, neuroendocrine tumors, transitional cell carcinoma
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Avelumab structure rendering